Alzheimer’s Disease

The experimental Alzheimer’s drug slowed decline in memory and thinking by 27% when compared with placebo, although 20% of patients reported adverse events. 

Model includes demographic information, brain imaging test results, and genetic biomarkers

Brain scans showed no adverse side effects in patients treated with Aduhelm for Alzheimer’s disease, a neurology clinic study has found.

News that Alzheimer’s drug lecanemab has reduced cognitive decline by 27% is receiving measured responses from prescribers as they await further data.

Researchers from the University of California, Irvine have been awarded a $47 million grant from the National Institute on Aging to develop animal models to study the biology behind Alzheimer’s disease.

The resulting wave of disease could further strain already limited long-term care resources, investigators say.

The narrative and dramatization of Alzheimer’s disease in the popular TV series “This is Us” may help reduce the stigma around dementia and promote family discussions about plans for aging, new...

An international group of clinicians and researchers have agreed that Alzheimer’s disease blood biomarkers are a significant breakthrough, but are not yet ready for general clinical and primary care...

Brexpiprazole reduces agitation in Alzheimer’s, late-stage study finds … Seniors skipping meds due to cost, survey finds … ‘Failure to thrive’ diagnostic code for seniors is problematic and dismissive,...

A new analysis of existing research suggests there is “good evidence” that drugs commonly used to treat attention deficit hyperactivity disorder also may be effective in treating Alzheimer’s disease.